Humacyte, Inc. (HUMA)
1.34
-0.05
(-3.60%)
USD |
NASDAQ |
Jun 10, 16:00
1.05
-0.29
(-21.64%)
Pre-Market: 08:59
Humacyte Enterprise Value : 314.72M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 314.72M |
| June 09, 2026 | 325.82M |
| June 08, 2026 | 323.60M |
| June 05, 2026 | 316.94M |
| June 04, 2026 | 348.03M |
| June 03, 2026 | 328.04M |
| June 02, 2026 | 325.82M |
| June 01, 2026 | 339.15M |
| May 29, 2026 | 305.84M |
| May 28, 2026 | 301.40M |
| May 27, 2026 | 272.54M |
| May 26, 2026 | 263.66M |
| May 22, 2026 | 250.34M |
| May 21, 2026 | 243.68M |
| May 20, 2026 | 220.85M |
| May 19, 2026 | 200.45M |
| May 18, 2026 | 216.68M |
| May 15, 2026 | 223.72M |
| May 14, 2026 | 239.24M |
| May 13, 2026 | 268.10M |
| May 12, 2026 | 219.26M |
| May 11, 2026 | 239.24M |
| May 08, 2026 | 252.56M |
| May 07, 2026 | 257.00M |
| May 06, 2026 | 235.53M |
| Date | Value |
|---|---|
| May 05, 2026 | 217.46M |
| May 04, 2026 | 222.54M |
| May 01, 2026 | 207.11M |
| April 30, 2026 | 204.11M |
| April 29, 2026 | 199.27M |
| April 28, 2026 | 205.38M |
| April 27, 2026 | 196.14M |
| April 24, 2026 | 172.63M |
| April 23, 2026 | 174.43M |
| April 22, 2026 | 173.72M |
| April 21, 2026 | 163.53M |
| April 20, 2026 | 169.86M |
| April 17, 2026 | 174.90M |
| April 16, 2026 | 168.99M |
| April 15, 2026 | 180.65M |
| April 14, 2026 | 170.66M |
| April 13, 2026 | 165.99M |
| April 10, 2026 | 160.51M |
| April 09, 2026 | 151.98M |
| April 08, 2026 | 161.86M |
| April 07, 2026 | 151.96M |
| April 06, 2026 | 161.53M |
| April 02, 2026 | 159.84M |
| April 01, 2026 | 148.63M |
| March 31, 2026 | 151.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Altimmune, Inc. | 44.14M |
| Protalix Biotherapeutics, Inc. | 115.41M |
| Agenus, Inc. | 380.97M |
| Amgen, Inc. | 227.56B |
| BioCryst Pharmaceuticals, Inc. | 2.699B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.62M |
| Revenue (Quarterly) | 0.495M |
| Total Expenses (Quarterly) | 18.11M |
| EPS Diluted (Quarterly) | -0.089 |
| Gross Profit Margin (Quarterly) | -311.7% |
| Profit Margin (Quarterly) | -3.56K% |
| Earnings Yield | -42.89% |
| Normalized Earnings Yield | -49.65 |